PFE.HM - Pfizer Inc

Hamburg - Hamburg Delayed Price. Currency in EUR
-0.35 (-1.00%)
At close: 03:32PM CEST
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close35.05
Bid34.50 x 0
Ask34.55 x 0
Day's Range34.70 - 35.30
52 Week Range33.85 - 52.50
Avg. Volume258
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateJul 26, 2023 - Jul 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PFE.HM

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Investor's Business Daily

      Pfizer's Approach To Hemophilia Is 'Certainty Differentiated' — Here's Why Shares Fell

      Pfizer said Tuesday its experimental hemophilia treatment cut down on bleeding episodes in a pivotal study. But Pfizer stock dipped.

    • Zacks

      Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

      The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

    • Zacks

      Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

      Pfizer (PFE) has received quite a bit of attention from users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

    • Reuters

      Pfizer's hemophilia therapy reduces bleeding in late-stage study

      U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients. The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said. Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.

    • Business Wire

      Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial

      NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl

    • Motley Fool

      Pfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?

      The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?

    • Zacks

      EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

      Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

    • Motley Fool

      The Top Healthcare Stocks to Buy With $100

      The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.

    • Motley Fool

      Investing $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income

      If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.

    • Motley Fool

      3 No-Brainer Stocks to Buy for Under $100 Right Now

      Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics):  Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.

    • Investor's Business Daily

      Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

      An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

    • The Wall Street Journal

      Next Covid Boosters to Target New Strain

      Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.


      Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.

      Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present at the annual meeting.

    • Zacks

      Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

      Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.

    • Yahoo Finance Video

      Pfizer weight loss drug may be as effective as competitors: Study

      Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.

    • Benzinga

      Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases

      The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should

    • Financial Times

      Brussels and Pfizer agree deal to cut supply of Covid vaccines

      Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes

    • Reuters

      UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract

      The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026. The agreement, first reported by Reuters earlier on Friday, comes after months of talks and amid pressure on Brussels from EU governments to secure a change to the contract because of a global glut of COVID-19 vaccine doses and low demand for boosters. The amended contract matches "evolving needs", said EU Health Commissioner Stella Kyriakides in a statement.

    • Motley Fool

      Why Pfizer Stock Slipped by 2% Today

      The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares.

    • PR Newswire

      Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting

      Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its expanding portfolio of approved and investigational cancer therapies during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6. A total of 15 abstracts, covering three approved medicines and one investigational therapy, will be presented underscoring the company's focus on pursuing targeted therapies for hard-to-treat cancers where few therapies e

    • Business Wire

      Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting

      NEW YORK, May 25, 2023--Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. Abstracts include new data from pivotal trials supporting ongoing regulatory reviews for three potential therapies, if approved, and new clinical data for six early pipeline assets. In addition, Pfizer will hig

    • Yahoo Finance Video

      Pfizer trades at pre-pandemic levels, frustrating investors

      Yahoo Finance health care reporter Anjalee Khemlani analyzes shares of pharmaceutical giant Pfizer as the FDA issues its full approval of the COVID-19 treatment drug Paxlovid.

    • Benzinga

      FDA Nods to Pfizer's Paxlovid for COVID-19: A Potential $8 Billion Lifesaver in 2023

      The FDA has approved Pfizer Inc's (NYSE: PFE) Paxlovid (nirmatrelvir and ritonavir) for mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. The FDA approval is based on safety and efficacy data from the EPIC clinical development program. The Phase 2/3 EPIC-HR study enrolled unvaccinated, non-hospitalized adults aged 18 years and older with confirmed COVID-19 at increased risk of progressing to severe disease. The data s

    • Motley Fool

      Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?

      Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.

    • AP Finance

      COVID pill Paxlovid gets full FDA approval after more than a year of emergency use

      Pfizer received full approval on Thursday for its COVID-19 pill Paxlovid that's been the go-to treatment against the coronavirus. More than 11 million prescriptions for Paxlovid have been dispensed since the Food and Drug Administration allowed emergency use in late 2021. The emergency status was based on early studies and was intended to be temporary pending follow-up research.